A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Aplastic Anemia & MDS International Foundation Return to top.
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Clinical Trial: NCT02520427

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

 

The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have relapsed/refractory Acute Myeloid Leukemia, and to determine the maximum tolerated dose and/or a biologically active dose. The study will be conducted in multiple sites and test increasing doses of AMG 330. The safety of subjects will be monitored by intensive assessment of vital signs, electrocardiograms, physical examinations, and laboratory tests.

Status: 
Recruiting
Study Date: 
Mon, 08/31/2015 ( ) to Sun, 05/16/2021 ( )
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
Intervention: 
Drug: AMG 330 0.5-960 µg/day cIV infusion in cycles from 14 to 28 days
Share with addtoany.com.